Amundi Asset Management US’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Amundi Asset Management US’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-19,828	Closed	-$83K	–	1732
2018 Q3	$83K	Hold	19,828	–	–	﹤0.01%	1533
2018 Q2	$77K	Buy	19,828 +2,797	+16%	+$18.6K	﹤0.01%	1486
2018 Q1	$108K	Buy	+17,031	New	+$141K	﹤0.01%	1402

Other funds holding MACK

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Sepio Capital Salt Lake City, Utah $1.84B AUM 18.57% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

WIM

Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Amundi Asset Management US's MACK Position: Q4 2018 in Review

Amundi Asset Management US sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q4 2018, closing a stake of 19,828 shares — an estimated $83K sold.

Amundi Asset Management US first reported a position in MACK in Q1 2018 and held it in 3 quarters. The position peaked at $108K in Q1 2018. 56 funds tracked by Wall St. Rank hold MACK as of Q4 2018.

Amundi Asset Management US reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
Amundi Asset Management US sold 19,828 Merrimack Pharmaceuticals, Inc. shares in Q4 2018, an estimated $83K.
Amundi Asset Management US first reported a position in Merrimack Pharmaceuticals, Inc. in Q1 2018 and held it in 3 quarters.
Amundi Asset Management US's Merrimack Pharmaceuticals, Inc. position peaked at $108K in Q1 2018.
56 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2018.

Based on Amundi Asset Management US's 13F filing for Q4 2018, filed 14 Feb 2019.